Ocular toxicity of fludarabine: a purine analog

References

• Blau IW, Schmidt-Hieber M, Leschinger N et al. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Ann. Hematol.86(8), 583–589 (2007).
   PubMed Web of Science ®Google Scholar
• Karp JE, Giles FJ, Gojo I et al. A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk. Res.32(1), 71–77 (2007).
   PubMedGoogle Scholar
• Montgomery JA, Hewson K. Nucleosides of 2-fluoroadenine. J. Med.Chem.12(3), 498–504 (1969).
   PubMed Web of Science ®Google Scholar
• Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs53(6), 1005–1037 (1997).
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgitt DP. Oral fludarabine. Drugs,63(21), 2317–2323 (2003).
   PubMedGoogle Scholar
• Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin. Pharm.41(2), 93–103 (2002).
   Google Scholar
• Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL,Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol.21(2), 474–477 (1982).
   PubMed Web of Science ®Google Scholar
• White EL, Shaddix SC, Brockman RW, Bennett LL, Jr. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res.42(6), 2260–2264 (1982).
   PubMed Web of Science ®Google Scholar
• Avramis VI, Plunkett W. Metabolism of 9-β-D-arabinosyl-2-fluoroadenine-5′-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv.1(1), 1–10 (1983).
   PubMedGoogle Scholar
• Noker PE, Duncan GF, El Dareer SM, Hill DL. Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat. Rep.67(5), 445–456 (1983).
   PubMedGoogle Scholar
• Keating MJ, O’Brien S, McLaughlin P et al. Clinical experience with fludarabine in hemato-oncology. Hematol. Cell Ther.38(Suppl. 2), S83–S91 (1996).
   Google Scholar
• Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the Phase I clinical investigation of fludarabine phosphate. Semin. Oncol.17(5 Suppl. 8), 18–32 (1990).
   PubMed Web of Science ®Google Scholar
• Hersh MR, Kuhn JG, Phillips JL et al. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother. Pharmacol.17(3), 277–280 (1986).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Etcubanas E, Budman DR et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest.20(7–8), 904–913 (2002).
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk. Lymphoma10(1–2), 49–56 (1993).
   PubMed Web of Science ®Google Scholar
• Foran JM, Oscier D, Orchard J et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with ‘low-grade’ non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J. Clin. Oncol.17(5), 1574–1579 (1999).
   PubMed Web of Science ®Google Scholar
• Oscier D, Orchard JA, Culligan D et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol. J.2(5), 316–321 (2001).
   PubMedGoogle Scholar
• Yildiz O, Ozguroglu M, Yanmaz MT et al. Paraneoplastic pemphigus associated with fludarabine use. Medical oncology24(1), 115–118 (2007).
   PubMedGoogle Scholar
• Johnson S, Smith AG, Loffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet347(9013), 1432–1438 (1996).
   PubMed Web of Science ®Google Scholar
• Montillo M, Ricci F, Tedeschi A. Role of fludarabine in hematological malignancies. Expert Rev. Anticancer. Ther.6(9), 1141–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Kontoyiannis DP, O’Brien S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann. Intern. Med.129(7), 559–566 (1998).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Mauro FR, Rahimi S. Late listeriosis after fludarabine plus prednisone treatment. Br. J. Haematol.87(2), 407–408 (1994).
   PubMedGoogle Scholar
• Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep.70(10), 1225–1228 (1986).
   PubMedGoogle Scholar
• Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res.46(11), 5953–5958 (1986).
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol.4(1), 74–79 (1986).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J. Clin. Oncol.12(10), 2216–2228 (1994).
   PubMed Web of Science ®Google Scholar
• Grever M, Leiby J, Kraut E et al. A comprehensive Phase I and II clinical investigation of fludarabine phosphate. Semin. Oncol.17(5 Suppl. 8), 39–48 (1990).
   PubMedGoogle Scholar
• Von Hoff DD. Phase I clinical trials with fludarabine phosphate. Semin. Oncol.17(5 Suppl. 8), 33–38 (1990).
   PubMed Web of Science ®Google Scholar
• Grever MR, Kopecky KJ, Coltman CA et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol.30(5–6), 457–459 (1988).
   PubMedGoogle Scholar
• Montserrat E, Lopez-Lorenzo JL, Manso F et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk. Lymphoma21(5–6), 467–472 (1996).
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Matutes E, Cunningham D et al. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk. Lymphoma14(Suppl. 2), 17–23 (1994).
   PubMed Web of Science ®Google Scholar
• Morgan AE. Chemotherapy-induced neurotoxicity. Cancer Control2(3), 235–242 (1995).
   PubMedGoogle Scholar
• Chee YL, Culligan DJ, Olson JA et al. Sight-threatening varicella zoster virus infection after fludarabine treatment. Br. J. Haematol.110(4), 874–875 (2000).
   PubMedGoogle Scholar
• Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J. Clin. Oncol.15(2), 458–465 (1997).
   PubMed Web of Science ®Google Scholar
• Stillman M, Navia B, Mast J. Delayed neurotoxicity associated with fludarabine. Neurology,35(Suppl. 1), 291 (1985).
   PubMedGoogle Scholar
• Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol.114(4), 800–809 (2001).
   PubMed Web of Science ®Google Scholar
• Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin. Cancer Res.2(4), 653–658 (1996).
   PubMed Web of Science ®Google Scholar
• Santini V, D’Ippolito G, Bernabei PA et al. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leuk. Res.20(1), 37–45 (1996).
   PubMedGoogle Scholar
• Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol.11(1), 116–124 (1993).
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia,7(3), 378–383 (1993).
   PubMedGoogle Scholar
• Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol.25(7), 793–798 (2007).
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet,370(9583), 230–239 (2007).
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med.343(24), 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Green S, Surwit EA, Hannigan EV, Alberts DS. Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study. Am. J. Clin. Oncol.13(5), 433–435 (1990).
   PubMedGoogle Scholar
• Chanan-Khan A, Miller KC, Takeshita K et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood,106(10), 3348–3352 (2005).
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Dmoszynska A, Rolinski J. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. Leuk. Res.31(3), 411–412 (2007).
   PubMed Web of Science ®Google Scholar
• Tam CS, Seymour JF, Prince HM et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica91(11), 1546–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Ritzel MW, Ng AM, Yao SY et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem.276(4), 2914–2927 (2001).
   PubMed Web of Science ®Google Scholar
• Mangravite LM, Badagnani I, Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur. J. Pharm.479(1–3), 269–281 (2003).
   PubMed Web of Science ®Google Scholar
• Nagase K, Tomi M, Tachikawa M, Hosoya K. Functional and molecular characterization of adenosine transport at the rat inner blood-retinal barrier. Biochim. Biophys. Acta1758(1), 13–19 (2006).
   PubMed Web of Science ®Google Scholar
• Badagnani I, Chan W, Castro RA et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J.5(3), 157–165 (2005).
   PubMed Web of Science ®Google Scholar
• Gray JH, Mangravite LM, Owen RP et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol. Pharmacol.65(3), 512–519 (2004).
   PubMed Web of Science ®Google Scholar
• Hutton JJ, Von Hoff DD, Kuhn J et al. Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res.44(9), 4183–4186 (1984).
   PubMed Web of Science ®Google Scholar
• Harvey WH, Fleming TR, Von Hoff DD, Katterhagen JG, Coltman CA Jr. Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Cancer Treat. Rep.71(12), 1319–1320 (1987).
   PubMedGoogle Scholar
• Balducci L, Blumenstein B, Von Hoff DD et al. Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study. Cancer Treat. Rep.71(5), 543–544 (1987).
   PubMedGoogle Scholar
• Weiss GR, Crowley J, Von Hoff DD et al. Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study. Cancer Treat. Rep.70(9), 1123–1124 (1986).
   PubMedGoogle Scholar
• Rainey JM, Hill JB, Crowley J. Evaluation of fludarabine phosphate in small cell carcinoma. A Southwest Oncology Group Study. Invest. New Drugs6(1), 45–46 (1988).
   PubMedGoogle Scholar
• Kantarjian HM, Childs C, O’Brien S et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am. J. Med.90(2), 223–228 (1991).
   PubMed Web of Science ®Google Scholar
• Hochster HS, Kim KM, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin’s low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J. Clin. Oncol.10(1), 28–32 (1992).
   PubMed Web of Science ®Google Scholar
• Cohen RB, Abdallah JM, Gray JR, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann. Intern. Med.118(2), 114–116 (1993).
   PubMed Web of Science ®Google Scholar